MedTrace Logo

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT04157686 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 957

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.

Conditions

  • Glabellar Lines
  • Lateral Canthal Lines

Interventions

DRUG

MT10109L Dose 1

MT10109L Dose 1 will be injected into the GL area

DRUG

MT10109L Dose 2

MT10109L Dose 2 will be injected into the LCL area

DRUG

MT10109L Dose 1 + Dose 2

MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • SangMi Park · Medytox Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-23
Primary Completion
2023-02-16
Completion
2023-02-16
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Germany
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04157686 on ClinicalTrials.gov